Albert B. Deisseroth

Albert B. Deisseroth's AcademicInfluence.com Rankings

Philosophy

#8530

World Rank

#11935

Historical Rank

Logic

#5562

World Rank

#6969

Historical Rank

philosophy Degrees

Albert B. Deisseroth

Biology

#11564

World Rank

#14968

Historical Rank

Cell Biology

#585

World Rank

#598

Historical Rank

Molecular Biology

#1789

World Rank

#1818

Historical Rank

Biochemistry

#1922

World Rank

#2063

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Albert B. Deisseroth Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Albert B. Deisseroth's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression (1995) (801)
Catalase: Physical and chemical properties, mechanism of catalysis, and physiological role. (1970) (533)
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. (1994) (508)
Chronic myelogenous leukemia: a concise update. (1993) (459)
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts (1995) (399)
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. (1995) (344)
p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. (1995) (300)
A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter (1993) (269)
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. (1995) (252)
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. (1995) (240)
Localization of the human α-globin structural gene to chromosome 16 in somatic cell hybrids by molecular hybridization assay (1977) (219)
Sjögren-type syndrome after allogeneic bone-marrow transplantation. (1977) (198)
Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. (1977) (192)
Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma (1978) (189)
Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups (1994) (185)
Expression of unusual immunophenotype combinations in acute myelogenous leukemia. (1993) (179)
Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. (1992) (170)
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. (2000) (169)
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. (1992) (165)
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. (1996) (159)
Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. (1992) (155)
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. (1990) (153)
A temperature‐sensitive mutant of human p53. (1994) (132)
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. (1972) (131)
Chromosomal localization of human β globin gene on human chromosome 11 in somatic cell hybrids (1978) (131)
Detection of Fusion Transcripts Generated by the Inversion 16 Chromosome in Acute Myelogenous Leukemia (1994) (122)
Interaction of nuclear proteins with an AP‐1/CRE‐like promoter sequence in the human TNF‐α gene (1994) (122)
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. (1996) (111)
Damage associated molecular pattern molecules. (2007) (110)
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. (1993) (107)
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. (1996) (106)
High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. (1995) (106)
Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. (1980) (105)
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. (1992) (99)
Development of chemotactic responsiveness in myeloid precursor cells: studies with a human leukemia cell line. (1980) (96)
Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. (1994) (96)
EBNA1 regulates cellular gene expression by binding cellular promoters (2009) (94)
Human α-globin gene expression following chromosomal dependent gene transfer into mouse erythroleukemia cells (1978) (92)
Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. (1995) (91)
Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. (1992) (90)
Tacrolimus and Minidose Methotrexate for Prevention of Acute Graft- Versus-Host Disease After Matched Unrelated Donor Marrow Transplantation (1996) (89)
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. (1995) (88)
The hemostatic imbalance of plasma-exchange transfusion. (1979) (87)
Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. (1992) (85)
Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? (1995) (85)
Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. (1991) (85)
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. (1993) (84)
Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. (1996) (82)
Allogeneic blood stem cell transplantation in advanced hematologic cancers (1997) (81)
An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells (2003) (79)
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (75)
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. (1994) (75)
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. (1989) (75)
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. (1997) (74)
Human gene marker/therapy clinical protocols. (1996) (73)
Tumor vascular targeting therapy with viral vectors. (2006) (72)
STAT3-mediated signaling in the determination of rod photoreceptor cell fate in mouse retina. (2004) (71)
Recent advances in the application of gene therapy to human disease. (1995) (69)
Novel DNA binding of p53 mutants and their role in transcriptional activation. (1993) (69)
Lymphocyte depletion by continuous flow cell centrifugation in rheumatoid arthritis: clinical effects. (1979) (68)
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. (1995) (66)
Loss of imprinting in disease progression in chronic myelogenous leukemia. (1998) (66)
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. (1992) (65)
P53 gene mutations in acute myelogenous leukaemia (1992) (63)
Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon (2003) (63)
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. (2001) (62)
Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation (1992) (62)
Identification of a population of bipotent stem cells in the HL60 human promyelocytic leukemia cell line. (1981) (62)
Prenatal gene tranfer: scientific, medical, and ethical issues: a report of the Recombinant DNA Advisory Committee. (2000) (59)
Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells (1999) (59)
Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. (1998) (59)
Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. (1994) (54)
Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. (1994) (53)
Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function. (1994) (52)
Acanthamoeba meningoencephalitis after bone marrow transplantation. (1994) (51)
Human gene marker/therapy clinical protocols. (1999) (51)
Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection (2004) (50)
Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. (2002) (50)
Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. (1995) (49)
Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. (1994) (49)
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. (1994) (48)
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. (1996) (48)
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. (1994) (46)
Granulocyte Transfusion Therapy of Experimental Pseudomonas Septicemia: Study of Cell Dose and Collection Technique (1978) (46)
Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. (1995) (46)
Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. (1994) (44)
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. (1994) (43)
Hemoglobin synthesis in somatic cell hybrids: globin gene expression in hybrids between mouse erythroleukemia and human marrow cells or fibroblasts. (1975) (43)
Human interferon regulatory factor 2 gene. Intron-exon organization and functional analysis of 5'-flanking region. (1994) (42)
Selective isolation of young erythrocytes for transfusion support of thalassemia major patients. (1981) (42)
Hla-matched platelet transfusion therapy of severe aplastic anemia. (1978) (41)
Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. (1998) (40)
Extinction of globin gene expression in human fibroblast × mouse erythroleukemia cell hybrids (1976) (39)
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. (1994) (39)
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. (1996) (39)
Plasma perfused over immobilized protein A for breast cancer. (1982) (38)
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia (1994) (38)
Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia (1991) (37)
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. (1992) (37)
Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells (2007) (36)
Nature of the change produced in catalase by lyophilization (1967) (36)
Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. (1998) (35)
Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. (1992) (35)
Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. (2004) (35)
An isoform of protein disulfide isomerase isolated from chronic myelogenous leukemia cells alters complex formation between nuclear proteins and regulatory regions of interferon-inducible genes. (1992) (35)
Chromosome 17p and p53 changes in lymphoma (1991) (35)
Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia (1998) (35)
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. (1996) (34)
HLA-matched platelet transfusion therapy of severe aplastic anemia. (1978) (34)
Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. (2007) (34)
Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy (2006) (33)
Hemoglobin synthesis in somatic cell hybrids: coexpression of mouse with human or chinese hamster globin genes in interspecific somatic cell hybrids of mouse erythroleukemia cells. (1975) (33)
Recent advances and current challenges in tumor immunology and immunotherapy. (2007) (33)
Activation of phenotypic expression of human globin genes from nonerythroid cells by chromosome-dependent transfer to tetraploid mouse erythroleukemia cells. (1979) (32)
Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. (1993) (31)
Granulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique. (1978) (31)
Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. (1997) (31)
L-Selectin Expression Enhances Clonogenesis of CD34+ Cord Blood Progenitors (1999) (31)
Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. (1994) (30)
Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. (1994) (29)
Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation (1981) (29)
Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. (1992) (28)
Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. (2004) (27)
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). (1993) (27)
Interferon regulatory factor 1 induces the expression of the interferon‐stimulated genes (1997) (27)
Ratio of bcl-xshort to bcl-xlong Is Different in Good- and Poor-Prognosis Subsets of Acute Myeloid Leukemia (1998) (27)
Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse. (1995) (27)
Liposomal delivery of oligodeoxynucleotides. (1996) (27)
Hemoglobin synthesis in somatic cell hybrids: independent segregation of the human alpha- and beta-globin genes. (1976) (26)
Improvement of PCR sequencing by formamide. (1991) (26)
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia (1999) (25)
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. (1996) (25)
Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr–abl positive 32D myeloid leukemia cells (1998) (25)
Vector Targeting Makes 5-Fluorouracil Chemotherapy Less Toxic and More Effective in Animal Models of Epithelial Neoplasms (2004) (25)
5q- chromosome. Evidence for complex interstitial breaks in a case of refractory anemia with excess blasts. (1994) (24)
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. (1996) (24)
Mobilization and exocytosis of specific (secondary) granules by human neutrophils during adherence to nylon wood in filtration leukapheresis (FL). (1978) (24)
Chromosomal localization of human beta globin gene on human chromosome 11 in somatic cell hybrids. (1978) (23)
Acquired alpha-thalassemia in preleukemia is due to decreased expression of all four alpha-globin genes. (1983) (23)
Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. (1999) (22)
Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer1 (2006) (22)
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. (1994) (22)
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. (1997) (22)
Regulatory factors specific for adult and embryonic globin genes may govern their expression in erythroleukemia cells. (1985) (21)
Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. (1995) (21)
Differentiation of carcinomatous and bacterial meningitis (1972) (21)
Expression of human α-globin genes in hybrid mouse erythroleukaemia cells depends on differentiated state of human donor cell (1980) (20)
Quinidine-induced liver disease. (1972) (20)
Results of retroviral and adenoviral approaches to cancer gene therapy (1998) (20)
Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. (1997) (19)
High and Low Levels of Cottontail Rabbit Papillomavirus E2 Protein Generate Opposite Effects on Gene Expression* (2001) (19)
Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy (2006) (19)
Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. (1994) (19)
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer (2006) (18)
Human interferon regulatory factor 1: intron-exon organization. (1992) (18)
Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. (1996) (17)
PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. (1995) (17)
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. (1998) (17)
Potential role of bcr-abl in the activation of JAK1 kinase. (1997) (17)
Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. (1996) (16)
Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. (1993) (16)
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. (1992) (15)
Interferon-gamma priming effects in the activation and deactivation of ISGF3 in K562 cells. (1993) (15)
Improved PCR sequencing with formamide. (1992) (15)
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. (1993) (15)
The gene product of CBFB-MYH11. (1996) (15)
Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model. (1997) (14)
Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells (2010) (14)
Changes in the translational activity of polyadenylated messenger RNA of HL60 promyelocytic leukemia cells associated with myeloid or macrophage differentiation. (1983) (14)
Antagonistic effects of ABL and BCRABL proteins on proliferation and the response to genotoxic stress in normal and leukemic myeloid cells. (1998) (13)
The purification and crystallization of beef erythrocyte catalase. (1969) (13)
TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases (2012) (13)
Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation. (1981) (13)
Pretreatment of filtration leukapheresis donors with colchicine. (1978) (13)
Platelet phosphorylase activity in the presence of activators and inhibitors of aggregation. (1970) (12)
p 53-independent Induction of WAF 1 / CIP 1 in Human Leukemia Cells Is Correlated with Growth Arrest Accompanying Monocyte / Macrophage Differentiation 1 (2006) (12)
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy. (1990) (12)
Chronic Myelogenous Leukemia: Molecular Approaches to Research and Therapy (1990) (12)
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. (1995) (11)
Methods for delivery of adenoviral vectors to tumor vasculature. (2007) (11)
The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle. (1992) (10)
The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element. (1994) (10)
Biological characterization of stem cell present in mobilized peripheral blood of CML patients. (1994) (10)
Development of a sensitive PCR to detect allele loss in a model hematopoietic neoplasm. (1994) (10)
Metabolic studies of histones and residual protein of rat liver nuclei. (1968) (10)
Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma. (2010) (10)
Regulatory role of the cyclic nucleotides in alloimmune lymphocyte mediated cytotoxicity. Effect of imidazole. (1973) (9)
Human gene marker/therapy clinical protocols. (1997) (9)
S1 nuclease analysis of alpha-globin gene expression in preleukemic patients with acquired hemoglobin H disease after transfer to mouse erythroleukemia cells. (1987) (9)
The use of chemotherapy resistance in cancer treatment. (1997) (9)
Isolation of hybrid cells that exhibit markers of erythroid differentiation. (1976) (9)
Evidence for multiple sites of regulation of heme synthesis in murine erythroleukemia cells. (1979) (9)
Effect of puromycin and cortisol pretreatment on the uptake of [14C]leucine into the globulins, whole histones and residual protein of the rat-liver nucleus (1969) (8)
Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). (1993) (8)
Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells. (2008) (8)
Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes (2006) (8)
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. (1994) (7)
Principles of bone marrow processing and progenitor cell/mononuclear cell concentrate collection in a continuous flow blood cell separation system. (1995) (7)
Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70. (1992) (7)
Comparison of the catalytic and physical properties of the components of lyophilized beef erythrocyte catalase with those of lyophilized beef liver catalase components. (1969) (7)
Adenoviral vectors and hematopoietic cells. (1997) (7)
Consistent Loss of the D 5 S 89 Locus Mapping Telomeric to the Interleukin Gene Cluster and Centromeric to EGR-1 in Patients With 5 q-Chromosome (2002) (7)
Recombinant adenoviral vector containing tumor-specific l-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test (2004) (7)
Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor, Interleukin-3 and Stem Cell Factor Effects In Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor (1992) (7)
Quantitive Expression of Proliferating Cell Nuclear Antigen by Western Blot (PCNAWB) in Peripheral Blasts Correlates with Remission Induciton in Patients with Acute Myelogenous Leukemia (1995) (7)
Identification of proteins binding to interferon-inducible transcriptional enhancers in hematopoietic cells. (1992) (6)
Effect of nucleotide concentration on specificity of sequence amplification. (1991) (6)
Peptides inhibitory for the transcriptional regulatory function of human papillomavirus E2. (2003) (6)
New Directions in the Biology and Therapy of Chronic Myeloid Leukemia (1992) (6)
Use of autotransplants in chronic myeloid leukaemia. (1992) (6)
Correlation of CD 2 Expression With PML Gene Breakpoints in Patients With Acute Promyelocytic Leukemia (2003) (6)
Retinoids and cancer therapy. (1992) (6)
The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function. (1994) (6)
Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. (1995) (6)
Adverse effects of molgramostim in marrow transplant recipients. (1993) (5)
The Use of theL-Plastin Promoter for Adenoviral-mediated , Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines 1 (2001) (5)
The first intron of human h-ras is regulated by p53 - mediation of specific activation by a p53-binding element. (1995) (5)
Adult leukemia. (1990) (5)
International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers (2006) (5)
Vector vaccination and vector targeted chemotherapy in solid tumors. (2009) (5)
CDS-Depleted Donor Lymphocyte Infusion as Treatment for Relapsed Chronic Myelogenous Leukemia After Allogeneic Bone Marrow Transplantation (2000) (5)
Characterization of an unique RNA initiated immediately upstream from human alpha 1 globin gene in vivo and in vitro: polymerase II-dependence, tissue specificity, and subcellular location. (1985) (4)
Faculty Opinions recommendation of Molecular definition of breast tumor heterogeneity. (2007) (4)
Human embryonic zeta-globin gene expression in mouse-human hybrid erythroid cell lines. (1995) (4)
Activation of class I HLA expression by TNF‐alpha and gamma‐interferon is mediated through protein kinase C‐dependent pathway in CML cell lines (1991) (4)
Expression of Epidermal Growth Factor Receptor and Human Papillomavirus E 6 / E 7 Proteins in Cervical Carcinoma Cells (1997) (4)
Normal and pathological functions of mammalian retroelements. (2005) (4)
Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. (1992) (4)
Cellular and molecular studies on globin gene expression. (1978) (4)
Expression of multidrug resistance (mdr-1) and p53 genes in hematologic cell systems: Implications for biology and gene therapy (1993) (3)
Correlation of cell proliferation inhibition and apoptosis induction with expression of human beta 5 integrin on hematopoietic cells. (1999) (3)
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells. (1986) (3)
International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China (2007) (3)
Clinical trials involving multidrug resistance transcription units in retroviral vectors. (1999) (3)
Novel compounds with antiproliferative activity against imatinib-resistant cell lines (2007) (3)
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes. (1990) (3)
Bone marrow transplantation for leukemia. (1993) (3)
Expression of human and mouse nonhistone chromosomal proteins in hybrid mouse erythroleukemia cells containing a single human chromosome. (1981) (3)
Novel therapeutic approaches for chronic myelogenous leukemia (1990) (3)
Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. A pilot study. (1996) (3)
, Martin and Infection Protein Leads to Clearance of Papillomas Vector Expressing the Papillomavirus E 2 Vaccination of Rabbits with an Adenovirus (2003) (2)
Genetic therapy using bone marrow transplantation. (1995) (2)
Interaction of the seed and the soil. (1994) (2)
Expression in Acute Myelogenous Leukemia (1992) (2)
Production of mouse globin in heterokaryons of mouse erythroleukaemia cells and human fibroblasts. (1977) (2)
CD2 expression and the PML-RAR gene. (1993) (2)
Study of markers of human erythroid differentiation in hybrid cells (1976) (2)
Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit. (2001) (2)
Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors (1990) (2)
Acquired a-thalassemia in preleukemia is due to decreased expression of all four a-globin genes (1999) (2)
Molecular therapy for cancer. (1998) (2)
Direct PCR sequencing with denaturants (formamide). (1996) (2)
CD2 expression and the PML-RAR gene [letter; comment] (1993) (2)
DNAase I nuclease digestion studies of the human zeta globin gene before and after transfer from the K562 cell to the mouse erythroleukemia cell. (1987) (2)
Laboratory findings in pulmonary embolism. (1971) (2)
Isolation of hybrid cell clones that contain deletion and non-deletion defects of alpha-thalassemia in man. (1980) (2)
Cell Kinetic, Molecular and Clinical Analysis of Growth Factor Sensitization of Myeloid Leukemia1 (1994) (2)
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. (1990) (2)
Future directions in molecular and genetic therapy for Leukemias and solid tumors (1990) (1)
The human multiple drug resistance gene (mdr-1) is used to confer chemoprotection upon hematopoietic progenitor cells in a clinical gene therapy trial setting for ovarian and breast cancer treatment (1996) (1)
Direct Polymerase Chain Reaction Sequencing with Denaturants (2000) (1)
Gene therapy of solid tumors and hematopoietic neoplasms. (1997) (1)
Mobility shift assay and southwestern gel analysis show that nuclear proteins from human leukemia cell lines bind 3 and 5 to the human zeta globin gene (1987) (1)
Regulation of adult and embryonic genes in human leukemia cells (1987) (1)
Platelet transfusion in aplastic patients: fatal thrombocytopenic hemorrhage in myeloblastic leukemia. (1991) (1)
Modulation of Cytotoxic T Lymphocyte Function by Cyclic 3′,5′-Mononucleotides (1974) (1)
New Drugs for CML (2007) (1)
Use of safety-modified retroviruses for identification of relapse after bone marrow transplantation (1993) (1)
Hemopoietic growth factors, oncogenes, and cytokines in clinical hematology : current aspects and future directions (1994) (1)
A new technique for mapping the human hemoglobin genes. (1976) (1)
Gene therapy: Chemoprotection, immunoenhancement, and modification of tumor cells (1993) (1)
Chronic myelogenous leukemia--update and future directions. (1994) (1)
EXPRESSION OF HUMAN α-Globin GENES IN HYBRID MOUSE ERYTHROLEUKEMIA CELLS (1980) (1)
Higher levels of expression of BCL-2 and BCL-XL in poor prognosis monosomy 5 and monosomy 7} acute myeloid leukemia (AML) cells than in good prognosis (inversion 16 and translocation 8;21) aml cells (1996) (1)
TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia (2008) (1)
Large-scale preparation of highly purified, frozen/thawed CD34 + , HLA-DR - hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting (1994) (1)
Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors (2010) (1)
A most Friendly meeting (1975) (1)
Methylphosphonate liposomal antisense oligonucleotides and methods for their preparation and use. (1994) (1)
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. (1992) (1)
Presence of P210bcrabl Is Associated with Decreased Expression of a Beta Chemokine C10 Gene in a P210bcrabl-Positive Myeloid Leukemia Cell Line (1999) (1)
Advances in the Biology and Treatment of Chronic Myelogenous Leukemia (1994) (1)
Tumor specific targeting of adenoviral vectors to cancer (2002) (1)
myelogenous leukemia Expression of unusual immunophenotype combinations in acute (2011) (1)
Molecular approaches to the diagnosis and treatment of cancer (1993) (1)
Vector Prime-Protein Boost Vaccine Induces 20 Fold Decrease in the Levels of CD44 + CD24 −/Low Cancer Stem Cells in Epithelial Neoplasms (2008) (0)
Vector vaccine overcomes anergy (2004) (0)
(gene mapping/cloning/cDNA/fibroblasts/molecular hybridizat (2016) (0)
Prospects for eradication of therapy-induced myelosuppression. (1990) (0)
How to do more with less. (1998) (0)
Presence of P2lObcrabl Is Associated with Decreased Expression of a Beta Chemokine CIO Gene in a P210bcrabl-Positive Myeloid Leukemia Cell Line (2007) (0)
Faculty Opinions recommendation of CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. (2011) (0)
Human gene marker/therapy clinical protocols. (1996) (0)
Cytokine/ chemotherapy interactions in myeloid leukemia: Clinical results and laboratory correlates (1994) (0)
human bone marrow long-term culture-initiating cells Stromal support enhances cell-free retroviral vector transduction of (2010) (0)
Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals. (1992) (0)
Vaccine for prevention of breast cancer. (2006) (0)
hematologic malignancies expressing the IL-2 receptor Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in (2011) (0)
Genetic therapy of human neoplastic disease. (1993) (0)
method: potential for predicting relapse promyelocytic leukemia by the fluorescence in situ hybridization Detection of residual leukemic cells in patients with acute (2013) (0)
Combination of vaccine with targeted chemotherapy reduced levels of CSC like (CD44+CD24- hematopoietic lineage negative {LIN-}) cells and improves outcome of cancer treatment (2008) (0)
Gene therapy of cancer (1997) (0)
Vaccination with the Ad-sig-TAA/ecdCD40L vector followed by vector targeting of chemotherapy completely suppresses the growth of subcutaneous deposits of H2N positive breast cancer in rH2N.Tg mice (2005) (0)
Vectors for Treatment of Metastatic Breast Cancer (2005) (0)
Human gene marker/therapy clinical protocols. (2000) (0)
G remissions of chronic myelogenous leukemia Polyclonal hematopoiesis in interferon-induced cytogenetic (2003) (0)
Oligonucleotides antisens de phosphonate de methyle de liposomes et procedes de preparation et d'utilisation (1994) (0)
Vector vaccine overcomes anergy. (2004) (0)
Chromosomal localization and regional mapping of the human globin genes. (1980) (0)
5' region of zeta-globin and GMCSF genes share binding site for nuclear proteins. (1988) (0)
Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia (1992) (0)
A new technique for mapping the human hemoglobin genes. (1976) (0)
Ad-sig-TAA/CD40L Vector Prime-TAA/CD40L Protein Boost Vaccine for Epithelial Neoplasms (2005) (0)
Tumor Specific Gene Expression and Tumor Specific Vector Replication for Systemic Chemotherapy Sensitization Treatment of Breast Cancer (2002) (0)
Pattern of Reconstitution and Relapse Following Autologous Bone Marrow Transplantation for Chronic Myelogenous Leukemia (2020) (0)
Vaccine for Cancer and Infectious Diseases (2007) (0)
Chronic myelogenous leukemia--recent advances in treatment and pathogenesis. (1986) (0)
Abstract 5911: A bicistronic adenoviral vector carrying cytosine deaminase and GM-CSF genes significantly improves antitumor immunity and overall survival in colon cancer (2018) (0)
Subcutaneous injection of the Ad-sig-TAA/ecdCD40L adenoviral vector encoding a CD40ligand/tumor associated antigen secretory protein generates T cell dependent cellular immunity against tumor cell lines for up to one year (2004) (0)
[Correlation of cell apoptosis induction with expression of human beta5 integrin on hematopoietic cells]. (2001) (0)
Keystone meeting on controversies in bone marrow transplantation : gene therapy workshop (1995) (0)
Presence of P 2 lObcrabl Is Associated with Decreased Expression of a Beta Chemokine CIO Gene in a P 210 bcrabl-Positive Myeloid Leukemia Cell Line (1998) (0)
Faculty Opinions recommendation of Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. (2013) (0)
Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer (1997) (0)
Regulation of Globin Gene Expression (2008) (0)
TAA/CD4OL composition/vaccine for malaria (2017) (0)
Subject Index Vol. 16, 1976 (1976) (0)
Effect of GM-CSF on tumor-specific immune response and antitumoral efficacy when combined with suicide gene therapy. (2009) (0)
Chromosomal transfer in mouse erythroleukemia cells shows that trans regulation mediates tissue specific and developmentally specific patterns of globin gene expression. (1985) (0)
following interferon therapy Philadelphia chromosome-positive chronic myelogenous leukemia Detection of minimal residual disease by polymerase chain reaction in (2011) (0)
44: Pre-clinical study of the effect of the As-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost vaccine in elderly recipients for suppression of recurrent cancer following allografting and donor lymphocyte infusions (DLI) (2007) (0)
Identification of a transcriptional nuclear regulatory protein which exhibits specificity for expression of adult genes. (1990) (0)
Molecular Diagnosis and Monitoring in Aml with Inversion 16 (inv16) (1993) (0)
and Cancer Overcomes Defects Acquired during Aging Vector Prime/Protein Boost Vaccine That (2006) (0)
Domain: Structural andFunctional Analysis oftheHumanInterferon Regulatory Factor 1GenePromoter (1993) (0)
Genetic therapy of human disease (1995) (0)
Platelet phosphorylase activity in the presence of activators and inhibitors of aggregation. (1970) (0)
Regulation of apoptosis in AMI, MDS and normal hematopoiesis (1996) (0)
Targeting of chemotherapy to Tie-2-receptor positive angiogenic endothelial cells of tumor vasculature. (2009) (0)
Faculty Opinions recommendation of Identification of a cell of origin for human prostate cancer. (2010) (0)
Vector Prime-Protein Boost Vaccine Induces Immune Response Against “Self-Antigens” Associated with Epithelial Neoplasms and Tumor Vascular Endothelial Cells. (2005) (0)
Vaccine for Cancer and Infectious Diseases (B194) (2007) (0)
1128. Ad-sig-TAA/ecdCD40L Vector Prime, TAA/CD40L Protein Boost Vaccine Breaks Tolerance for Tumor Assoicated Antigens (TAA) and Suppresses Growth and Metastasis of Epithelial Neoplastic Cells (2005) (0)
Genetic Systems for the Diagnosis and Treatment of Human Disease (2004) (0)
Human gene marker/therapy clinical protocols. (1999) (0)
444. A New Vector Which Targets Breast Cancer and Its Vasculature (2005) (0)
Title Page / Contents / Preface (1994) (0)
Use of an adenoviral vector containing the prodrug activation unit cytosine deaminase for purging bone marrow from breast cancer cells (1997) (0)
Donor lymphocyte infusions from Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost (VPP) vaccinated allodonors decrease tumor cell growth post allograft (2007) (0)
Methods for Chemoprotection and Chemosensitization : MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells. (2000) (0)
Liposomal antisense methyl phosphonate oligo-nucleotides and process for their preparation and their use (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Albert B. Deisseroth?

Albert B. Deisseroth is affiliated with the following schools:

MD Anderson Cancer Center

Albert B. Deisseroth's Academic­Influence.com Rankings

Why Is Albert B. Deisseroth Influential?

Albert B. Deisseroth's Published Works

Published Works

What Schools Are Affiliated With Albert B. Deisseroth?

Albert B. Deisseroth's AcademicInfluence.com Rankings